June Zhao

935 total citations
16 papers, 711 citations indexed

About

June Zhao is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, June Zhao has authored 16 papers receiving a total of 711 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in June Zhao's work include Diabetes Treatment and Management (7 papers), Potassium and Related Disorders (6 papers) and Magnesium in Health and Disease (5 papers). June Zhao is often cited by papers focused on Diabetes Treatment and Management (7 papers), Potassium and Related Disorders (6 papers) and Magnesium in Health and Disease (5 papers). June Zhao collaborates with scholars based in United States, Sweden and China. June Zhao's co-authors include Wenying Yang, Conrad Tou, Ingrid Gause‐Nilsson, Chang Yu Pan, Meijing Wu, Xiaoyan Yan, Wenbin Liu, Zheng Gu, Yanfang Zhao and Jia He and has published in prestigious journals such as BMC Public Health, Clinical Journal of the American Society of Nephrology and Nephrology Dialysis Transplantation.

In The Last Decade

June Zhao

15 papers receiving 698 citations

Peers

Countries citing papers authored by June Zhao

Since Specialization

Citations

This map shows the geographic impact of June Zhao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by June Zhao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites June Zhao more than expected).

Fields of papers citing papers by June Zhao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by June Zhao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by June Zhao. The network helps show where June Zhao may publish in the future.

Co-authorship network of co-authors of June Zhao

This figure shows the co-authorship network connecting the top 25 collaborators of June Zhao. A scholar is included among the top collaborators of June Zhao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with June Zhao. June Zhao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	HARMONIZE Asia: A Phase III Randomized Study to Investigate the Efficacy and Safety of Sodium Zirconium Cyclosilicate in Patients with Hyperkalemia in China 2024 ·Clinical Therapeutics ·Xinling Liang, Wanhong Lu, Xueqing Yu, Hong Cheng, Qiang He, (unknown), Zhaohui Ni, (unknown), (unknown), Wei Chen, Rong Li, June Zhao, Yong Zhang, Vera Lisovskaja, (unknown)	0
2	Phase I Study of the Pharmacodynamics and Safety of Sodium Zirconium Cyclosilicate in Healthy Chinese Adults 2022 ·Clinical Pharmacology in Drug Development ·TT Cheung, (unknown), June Zhao, Yulin Qin, Mats Någård	2
3	A phase 3 multicenter open-label maintenance study to investigate the long-term safety of sodium zirconium cyclosilicate in Japanese subjects with hyperkalemia 2020 ·Clinical and Experimental Nephrology ·Naoki Kashihara, Yoshimitsu Yamasaki, Takeshi Osonoi, Hiromasa Harada, Yugo Shibagaki, June Zhao, Hyosung Kim, Toshitaka Yajima, Nobuaki Sarai	12
4	Efficacy and Safety of Sodium Zirconium Cyclosilicate for Hyperkalaemia: The Randomized, Placebo-Controlled HARMONIZE-Global Study 2020 ·ESC Heart Failure ·Faı̈ez Zannad, Bang‐Gee Hsu, Yoshitaka Maeda, Sug Kyun Shin, (unknown), (unknown), Stefan Eklund, June Zhao	60
5	Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia 2019 ·Clinical Journal of the American Society of Nephrology ·Bruce Spinowitz, Steven Fishbane, Pablo E. Pérgola, Simon D. Roger, Edgar V. Lerma, Javed Butler, Stephan von Haehling, Scott Adler, June Zhao, Bhupinder Singh, Philip T. Lavin, Peter A. McCullough, Mikhail Kosiborod, David Packham, (unknown)	126
6	Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study 2019 ·Nephrology Dialysis Transplantation ·Simon D. Roger, Philip T. Lavin, Edgar V. Lerma, Peter A. McCullough, Javed Butler, Bruce Spinowitz, Stephan von Haehling, Mikhail Kosiborod, June Zhao, Steven Fishbane, David Packham	41
7	Saxagliptin add‐on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double‐blind, placebo‐controlled trial 2017 ·Diabetes Obesity and Metabolism ·Yingli Chen, Xiao-Min Liu, Quanmin Li, Jianhua Ma, Xiaofeng Lv, Lixin Guo, Changjiang Wang, Yongquan Shi, Yanbing Li, Eva Johnsson, Mei Wang, June Zhao, (unknown)	10
8	Efficacy and safety of saxagliptin in combination with metformin as initial therapy in C hinese patients with type 2 diabetes: R esults from the START study, a multicentre, randomized, double‐blind, active‐controlled, phase 3 trial 2017 ·Diabetes Obesity and Metabolism ·Jingtao Dou, Jianhua Ma, Jun Liu, Changjiang Wang, Eva Johnsson, Hui Yao, June Zhao, Changyu Pan	18
9	Dapagliflozin as add‐on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial 2017 ·Journal of Diabetes ·Wenying Yang, Jianhua Ma, Yiming Li, Yanbing Li, Zhiguang Zhou, Jae Hyeon Kim, June Zhao, Agata Ptaszynska	45
10	Metformin extended‐release versus immediate‐release: A n international, randomized, double‐blind, head‐to‐head trial in pharmacotherapy‐naïve patients with type 2 diabetes 2017 ·Diabetes Obesity and Metabolism ·Naresh Aggarwal, Anuj Singla, Chantal Mathieu, Eduard Montanya, Andreas Pfeiffer, Eva Johnsson, June Zhao, Nayyar Iqbal, Clifford J. Bailey	31
11	Pharmacokinetic Study of Saxagliptin in Healthy Chinese Subjects 2012 ·Clinical Drug Investigation ·Haiyan Li, (unknown), Conrad Tou, Chirag G. Patel, June Zhao	11
12	Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial 2011 ·Diabetes Research and Clinical Practice ·Wenying Yang, Chang Yu Pan, Conrad Tou, June Zhao, Ingrid Gause‐Nilsson	88
13	Efficacy and safety of saxagliptin in drug‐naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial 2011 ·Diabetes/Metabolism Research and Reviews ·Chang Yu Pan, Wenying Yang, Conrad Tou, Ingrid Gause‐Nilsson, June Zhao	70
14	Health related quality of life measured by SF-36: a population-based study in Shanghai, China 2008 ·BMC Public Health ·Rui Wang, Cheng Wu, Yanfang Zhao, Xiaoyan Yan, Xiuqiang Ma, Meijing Wu, Wenbin Liu, Zheng Gu, June Zhao, Jia He	134
15	Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study 2006 ·Clinical Therapeutics ·Jianguo Li, June Zhao, (unknown), Tommy Andersson, (unknown), Marta Illueca, Per Lundborg	32
16	Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study 2006 ·Clinical Therapeutics ·June Zhao, Jianguo Li, (unknown), Tommy Andersson, (unknown), Marta Illueca, Per Lundborg	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact